Batm Advanced Communicat... Dividends - BVC

Batm Advanced Communicat... Dividends - BVC

Buy
Sell
Best deals to access real time data!
Level 2 Basic
Monthly Subscription
for only
£62.08
Silver
Monthly Subscription
for only
£17.37
UK/US Silver
Monthly Subscription
for only
£30.59
VAT not included
Stock Name Stock Symbol Market Stock Type Stock ISIN Stock Description
Batm Advanced Communications Ld BVC London Ordinary Share IL0010849045 ORD ILS0.01
  Price Change Price Change % Stock Price Last Trade
-1.90 -2.16% 86.00 16:35:12
Open Price Low Price High Price Close Price Previous Close
90.00 85.50 91.80 86.00 87.90
more quote information »
Industry Sector
TECHNOLOGY HARDWARE & EQUIPMENT

Batm Advanced Communicat... BVC Dividends History

Announcement Date Type Currency Dividend Amount Period Start Period End Ex Date Record Date Payment Date Total Dividend Amount
07/03/2011FinalUSD0.831/12/200931/12/201022/06/201124/06/201118/07/20110.8
08/02/2010FinalUSD1.3531/12/200831/12/200930/06/201002/07/201026/07/20111.35
17/03/2009FinalUSD0.6931/12/200731/12/200824/06/200926/06/200920/07/20090.69
04/03/2008FinalUSD131/12/200631/12/200725/06/200827/06/200818/07/20081
15/03/2000FinalUSD0.531/12/199831/12/199908/05/200012/05/200021/06/20000.5
26/04/1999FinalUSD0.531/12/199731/12/199810/05/199901/01/197021/06/19990.5

Top Dividend Posts

DateSubject
18/5/2021
07:03
wizzkid211: RNS Number : 9137Y BATM Advanced Communications Ld 18 May 2021 LEI: 213800FLQUB9J289RU66 18 May 2021 BATM Advanced Communications Limited ("BATM" or "the Group") BATM commences delivery of saliva-based RT-PCR and new rapid lateral flow COVID-19 tests Italian Olympic Committee to use BATM's saliva COVID-19 test for Tokyo Olympics BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, announces that it has commenced delivery of two new diagnostic tests for SARS-CoV-2 (COVID-19) and that the Italian Olympic Committee intends to use the Group's saliva-based RT-PCR test for the upcoming Olympic Games in Japan. Saliva-based RT-PCR test Further to the Group's announcement of 11 March 2021, BATM is pleased to confirm that it has commenced supplying its test that uses self-collected saliva samples to diagnose COVID-19 using the RT-PCR technique. The initial customers are public health authorities in Italy that are using the tests in schools and elderly care homes where there is a particular benefit for having a non-invasive sample collection method without compromising diagnostic accuracy. The provision of the tests is due to be expanded to several other groups as production increases. The test is also due to be used by the Italian Olympic Committee for the Olympic Games that are scheduled to commence in Japan in July. This follows the Italian Olympic Committee selecting two labs to provide testing for the tournament, one of which uses only the Group's antigen RT-PCR kits for COVID-19 testing, including the latest saliva-based test. The test involves the individual spitting into a collector tube rather than deep swabbing via the nose (nasopharyngeal swab) or back of the throat (oropharyngeal swab). It is based on the Group's antigen RT-PCR kit that has five (4+1) gene discovery capability, which enables detection even with a very low viral load and has 100% accuracy for specificity and sensitivity. The test can be administered without the need for trained healthcare workers in full body personal protective equipment, offering advantages in terms of speed of sample collection as well as lab processing and being more cost effective than the RT-PCR process for standard swab-based tests. The Group is producing the test at its Adaltis facility in Rome, Italy, which continues to increase manufacturing output. More information can be found here . Rapid lateral flow test BATM is also pleased to announce the commercial launch of the RAPiDgen(R) SARS-CoV-2 Ag test, which is an easy-to-use rapid test that gives results in 8-15 minutes. The test detects SARS-CoV-2 antigens, using the lateral flow method, in samples collected with a nasal (nostril) swab. The test consists of a small self-contained device and a nasal swab: after collecting a nasal secretion sample, the swab is placed into an opening in the device, swirled and then the cap clicked to a different direction. This compares with commonly available rapid tests that require the individual to prepare the test by pouring a buffer liquid into an extraction tube and, after swirling the swabbed sample in the extraction tube, dropping liquid onto a test strip. The RAPiDgen(R) SARS-CoV-2 Ag has undergone validation testing by hospitals in Israel and Europe where it has demonstrated sensitivity in excess of 95%. The test has been developed by the Group's Adaltis subsidiary and Gamidor Diagnostics ("Gamidor"). Gamidor is part of the Gamida for Life B.V. group that is also a partner in the Group's Ador Diagnostics associate company. The rapid test is being marketed under the Adaltis brand and sold under a revenue-share agreement with Gamidor. Production has commenced at Gamidor's facility in Israel with initial deliveries being to public health authorities. Negotiations are also underway to establish another production line for this test in Europe. Dr Zvi Marom, CEO of BATM, said: "I am delighted with the performance of our diagnostic tests - both commercially and medically. Our COVID-19 tests have demonstrable advantages compared with others available in the market in terms of accuracy, ease-of-use and cost effectiveness. "With the rollout of our saliva-based and rapid diagnostic kits, we now offer a full range of tests that can provide a comprehensive solution for tackling the pandemic. We continue to receive strong demand for our COVID-19 tests - and, in particular, we are honoured that the Italian Olympic Committee will be using our saliva tests to support Italy's Olympic journey. "At the same time, we expect this technology enabling precise diagnoses using saliva samples to be applied to diseases beyond COVID-19. It would be particularly beneficial for tests used to quickly differentiate between illnesses to provide an accurate diagnosis, such as our multi-pathogen respiratory test. We are also continuing to work with our academic and business partners to develop other innovative diagnostic solutions that we believe are at the forefront of the battle against infectious disease. "We are very proud of what we have achieved and very excited about what's still to come, and we look forward to updating the market in due course." Enquiries:
14/5/2021
09:15
wizzkid211: Do BATM Advanced Communications's (LON:BVC) Earnings Warrant Your Attention? BATM Advanced Communications's Improving Profits Over the last three years, BATM Advanced Communications has grown earnings per share (EPS) like young bamboo after rain; fast, and from a low base. So I don't think the percent growth rate is particularly meaningful. As a result, I'll zoom in on growth over the last year, instead. Like a firecracker arcing through the night sky, BATM Advanced Communications's EPS shot from US$0.0093 to US$0.022, over the last year. You don't see 139% year-on-year growth like that, very often. The best case scenario? That the business has hit a true inflection point. simplywall.st/stocks/gb/tech/lse-bvc/batm-advanced-communications-shares/news/do-batm-advanced-communicationss-lonbvc-earnings-warrant-you
19/4/2021
12:13
lsoc85: "Dividend The Board of BATM has resolved to recommend the distribution of a dividend for full year 2020. In accordance with Israeli law, a dividend can only be declared following the publication of the audited annual report and accounts. Accordingly, we will provide further details in due course."
12/4/2021
07:05
wizzkid211: Strategic partnership for Network Function Virtualisation BATM's Telco Systems subsidiary partners with albis-elcon for joint offer for tier 1 customers BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, announces that its Telco Systems subsidiary has formed a strategic partnership with albis-elcon, a supplier of networking products and systems to communications service providers in the telecommunications industry, to jointly offer the Group's network function virtualisation ("NFV") solution, which represents a further route to market. The Group's NFVTime virtualisation technology has been integrated into albis-elcon's new service delivery platform, uSphir, and optimised for operating with albis-elcon's products and systems for network management. uSphir has been developed to enable telecommunications operators to create virtual software-based networks (using BATM's operating system), which will allow them to quickly deploy virtualised business services to their end customers, that operate seamlessly with their existing network management systems and hardware provided by albis-elcon. In accordance with BATM's revenue model for NFVTime, it will receive a monthly license fee for each end point deployed by a customer. With support from Telco Systems, albis-elcon has commenced marketing uSphir to its customer base, which primarily consists of tier 1 telecommunications operators in Europe and Latin America. These are new geographies for BATM's networking business, which focuses on the US market.
26/3/2021
09:41
cumnor: Agree, Deeker. I've been here for years-adding and selling so have done very well and still have a big holding and see this as a really decent-multi billion-company in a few years and will stay the course. But what a frustrating shower from the PR point of view-doesn't sing its praises nearly half enough, from the covid developments, lab analysers across the whole infectious disease programme and now this PCCW stuff with Telco-which imo could be huge. But not a whimper from BVC-just a subtle titbit from Telco-rubbish about the 24th and then.......Zilch. Other companies would be banging the drum about these developments and achievements-but not Zvi. Clearly his priorities are elsewhere. Whatever the SP-and it will do well eventually-back to the monotony of waiting while the drones in their PR department wither on the vine. TG for the rest of my portfolio, incl a lot of US gamers/gambling stocks which at least generate a bit of excitement every now and then-unlike BVC.
11/3/2021
07:21
capitalist: I like the sound of it... BATM launches no-swab saliva-based COVID-19 test New self-collected saliva-based RT-PCR test significantly improves sample collection process and turnaround time while maintaining diagnostic accuracy BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, announces that it has launched a new molecular diagnostics kit that uses self-collected saliva samples to test for SARS-CoV-2 (COVID-19). This significantly improves the sample collection process compared with existing swabbing methods while, as an RT-PCR test, maintaining diagnostic accuracy. The Group has commenced taking orders and expects to begin delivering the kit in April. This new kit, which is part of Adaltis' MOLgen product range, consists of reagents that have been developed to accurately detect SARS-CoV-2 in saliva samples that are collected by an individual chewing a cotton ball for 30 seconds and then spitting it (or spitting directly) into a small plastic collector tube (a Salivette). It uses the RT-PCR technique, which ensures the highest levels of diagnostic accuracy compared with other saliva-based tests currently available in the market that primarily use the lateral flow method, which are far less accurate causing many false negatives and positives. The reagents are based on the Group's existing COVID-19 antigen kit that tests samples collected via swabbing the upper (via the nose) and middle parts of the throat or fluid from the lungs , and which has five (4+1) gene discovery capability (compared with most kits on the market having three gene discovery capability or less) to enable detection even with a very low viral load. The new test has 100% accuracy for both specificity and sensitivity. By the individual collecting a saliva sample, the test can be administered without the need for any trained healthcare workers in full body personal protective equipment. The test also has the advantage of being non-invasive and comfortable compared with swabbing via the nose (nasopharyngeal swab) or back of the throat (oropharyngeal swab). As a result, it is a far simpler and quicker solution, and has particular benefits for testing children and people with disabilities where the existing swabbing methods can cause distress or the tests are not possible to administer at all. Other benefits of the new test include: -- Processing times at the laboratory are significantly reduced as the RNA extraction phase that is required for the existing swabbing methods before putting the samples into the PCR instrument is not needed for the Group's saliva-based test (which operates under a protocol developed at Yale University). The RNA extraction phase is also expensive and the main cause of contaminations that result in false diagnoses. -- All standard PCR instruments can execute this test at a rate of c. 150-180 per hour, which (including the extraction phase) is approximately five times the rate for a nasopharyngeal test. One person is able to operate several instruments at the same time, which is very difficult with tests based on the existing swabbing methods. In addition, the instruments are able to be transported and set up in a mobile location. As a result, one operator can manage in excess of 1,000 tests per hour and can be deployed to where needed, such as the site of a school, sports event or on a cruise ship. -- It negates the risk of false negatives that can arise due to a badly performed nasopharyngeal swab. This new kit, which is CE certified, is able to detect all known variants of COVID-19, including in people who are asymptomatic. It has been validated by leading research and medical institutions in Italy. The test can be processed using Adaltis' AMPLilab instrument or any standard PCR instrument. The Group can also provide the sample collectors. Dr Zvi Marom, CEO of BATM, said: "We are extremely proud to have launched this new saliva-based COVID-19 test for samples that are self-collected without the need for swabbing. This greatly simplifies the testing process to increase speed and reduce cost while maintaining the same high level of diagnostic accuracy. Despite the excellent progress that has been made with vaccinations, we believe that COVID-19 will be with us for quite some time and so solutions such as our new saliva test will be invaluable for providing the ongoing testing required in places where people gather such as schools and leisure venues. We have already received particular interest from cruise lines and professional sports teams who see this test as enabling a safe return to more normal life. We look forward to commence shipping this product shortly and to delivering further innovative diagnostic solutions for COVID-19 and other infectious diseases in the near future."
01/3/2021
07:02
wizzkid211: BATM Advanced Communications Ld Update on Sale of NGSoft March 01 2021 - 02:00AM UK Regulatory (RNS & others) TIDMBVC RNS Number : 6021Q BATM Advanced Communications Ld 01 March 2021 LEI: 213800FLQUB9J289RU66 1 March 2021 BATM Advanced Communications Limited ("BATM" or "the Group") Update on Sale of NGSoft Further to the Group's announcement of 12 January 2021, BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, announces that it has exercised its option to sell NG Soft Ltd. ("NGSoft"), a subsidiary of the Group, for NIS 105.1m (approximately $33m) to Aztek Technologies (1984) Ltd., a provider of ICT cloud services in Israel and a portfolio company of SKY Fund (the "Buyer"). The Group and the Buyer have entered into a share purchase agreement pursuant to which the Buyer will purchase the entire issued share capital of NGSoft for a total consideration of NIS 105.1m (c. $33m), of which the Group will receive a total of NIS 93.7m (c. $29m) in cash. The Group's consideration includes a NIS 15.5m loan repayment from NGSoft and a NIS 2.1m dividend payment, which will be received prior to completion, and the remaining NIS 76.1m will be received on completion. Certain employees of NGSoft will receive the balance of NIS 11.4m through cash out of their employee options and rights on completion. Completion, which is subject to the receipt of approval from the Israel Competition Authority, is expected to occur by the end of March 2021. The Group intends to invest the proceeds of the sale to strengthen its innovation and commercialisation engine organically and through acquisition to enable the Group to accelerate its core activities - in particular, in network function virtualisation ("NFV") and molecular diagnostics. The Board of BATM believes these areas offer transformational growth opportunities in the short- to medium-term. In addition, the disposal of NGSoft, combined with the increased contribution to Group revenue from molecular diagnostics and NFV, will support the anticipated improvement in gross margin for 2021. NGSoft is a software and digital services company that provides creative digital and technology solutions. Its development activities do not include any of the Group's NFV or cyber solutions. In 2020, NGSoft generated a profit before tax of $2.4m and as at 31 December 2020 it had gross assets of $22.5m. Dr Zvi Marom, Chief Executive Officer of BATM, said: "We are pleased to be, once again, generating value from the sale of a part of our portfolio that is non-core to our future. We will be able to use the proceeds from this transaction to accelerate the areas of our business that we believe will provide transformational growth opportunities. This follows an extremely successful 2020, with significant strategic progress in both the Bio-Medical and Networking & Cyber division, and further strengthens our foundations. As a result, we remain very excited about our future and look forward to continuing to deliver shareholder value." Enquiries:
11/2/2021
18:12
wizzkid211: BATM Advanced Communications Ld FTSE Nationality Review February 11 2021 - 12:38PM UK Regulatory (RNS & others) TIDMBVC RNS Number : 8693O BATM Advanced Communications Ld 11 February 2021 LEI: 213800FLQUB9J289RU66 11 February 2021 BATM Advanced Communications Limited ("BATM" or "the Group") FTSE Nationality Review BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, notes that in the FTSE Nationality Review of Companies published by FTSE Russell on Wednesday 3 February 2021, the Group's nationality was reassigned from the UK to Israel. This change, which is scheduled to take effect from 22 March 2021, was pursuant to rule 5.1.6 of the Ground Rules of the FTSE UK Index Series. BATM is committed to maintaining its membership of the FTSE UK Index Series. As such, the Board of BATM, acknowledging the FTSE Russell rules in determining the nationality of an issuer, will investigate the available options for achieving this objective. BATM anticipates that this process will require 12 months. A further update will be made to the market in due course.
01/2/2021
07:44
james dean: 01/02/2021 7:00am UK Regulatory (RNS & others) Batm Advanced Communicat... (LSE:BVC) Monday 1 February 2021 RNS Number : 4589N BATM Advanced Communications Ld 01 February 2021 LEI: 213800FLQUB9J289RU66 1 February 2021 BATM Advanced Communications Limited ("BATM" or "the Group") Trading Update and Notice of Results BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, provides the following update on trading for the year ended 31 December 2020 ahead of announcing its annual results on Monday 22 February 2021. As stated in the interim results announcement, the Group entered the second half of 2020 with a substantially higher backlog than at the same point in the prior year. This momentum continued through the second half, with stronger than anticipated demand for the Group's diagnostics solutions towards the end of the year as the second wave of the COVID-19 pandemic spread across the globe. Consequently, BATM expects revenue for full year 2020 to be at least $180m - significantly ahead of the upgraded market expectations - representing annual growth of over 45% and, consequently, EBITDA to be substantially ahead of market expectations. The substantial growth over the previous year was driven by the Bio-Medical division. In particular, the Diagnostics unit rapidly developed testing kits in response to the outbreak of COVID-19 and received strong demand throughout the year for its reagents and instruments. These sales were primarily to public health authorities in Europe and South East Asia, and the Group has continued to receive significant orders for its diagnostic solutions into 2021. The Eco-Med unit also contributed to the exceptional performance of the Bio-Medical division in 2020 with the manufacture of critical care ventilators. The Networking & Cyber division remained resilient despite the restrictions on travel and ability to install equipment in customers' premises due to global lockdowns. In addition, the Group continued to make significant progress with its network function virtualisation ("NFV") solution - which the Group expects to become a key growth engine of the business - securing its first tier 1 customer for NFVTime with a three-year licensing agreement and c onducting several successful proofs-of-concept with tier 1 operators in Europe and APAC, including Vodafone. The Group will provide further detail in its full year results announcement. Full Year Results Presentation Dr Zvi Marom, Chief Executive Officer, and Moti Nagar, Chief Financial Officer, will be hosting a presentation via webinar for investors and analysts at 2.00pm GMT on Monday 22 February 2021. To register to participate, please contact clairenorbury@luther.co.uk Enquiries:
12/1/2021
07:02
wizzkid211: BATM Advanced Communications Ld BATM enters option agreement to sell NGSoft January 12 2021 - 02:00AM UK Regulatory (RNS & others) Alert Print Share On Facebook TIDMBVC RNS Number : 3160L BATM Advanced Communications Ld 12 January 2021 LEI: 213800FLQUB9J289RU66 12 January 2021 BATM Advanced Communications Limited ("BATM" or "the Group") BATM enters option agreement to sell NGSoft for c. $33m Disposal of legacy software services subsidiary to generate funds for acceleration of core activities BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, announces that it has entered into an option agreement (the "Option Agreement") to sell NG Soft Ltd. ("NGSoft"), a subsidiary of the Group, for NIS 105.1m (approximately $33m) in cash to Aztek Technologies (1984) Ltd., a provider of ICT cloud services in Israel and a portfolio company of SKY Fund (the "Buyer"). Background to the transaction BATM is focused on core areas of activity, underpinned by the Group's portfolio of intellectual property, that it expects will offer transformational growth opportunities in both its Networking & Cyber and Bio-Medical divisions. In particular, in 2020, the Group achieved fundamental milestones in progressing the development of its network function virtualisation ("NFV") activities, including a successful proof-of-concept of its NFVTime solution with Vodafone and securing its first tier 1 customer with a multi-year licensing agreement. In medical diagnostics, the Bio-Medical division rapidly produced multiple solutions in response to the COVID-19 outbreak that are experiencing substantial demand as the global pandemic continues. As previously stated, BATM continuously seeks opportunities to unlock shareholder value from Group subsidiaries that are considered non-core to the future of the Group. NGSoft is a software and digital services company that provides creative digital and technology solutions. Its development activities do not include any of the Group's NFV or cyber solutions. Accordingly, the Board believes that it would be in the best interests of BATM and of all shareholders to generate value from the sale of NGSoft and invest the proceeds to accelerate the Group's core activities in accordance with its strategic plan. Terms of the transaction Under the terms of the Option Agreement, BATM has the option, but not obligation, to sell the entire issued share capital of NGSoft for a total cash consideration of NIS 105.1m (c. $33m), of which the Group would receive a total of NIS 93.7m (c. $29m). The Group's consideration includes a NIS 15.5m loan repayment from NGSoft and a NIS 2.1m dividend payment, both to be received upon the exercise of the option. Certain employees of NGSoft would receive the balance of NIS 11.4m through cash out of their employee options and rights on completion. In the event that the option is exercised by BATM, a share purchase agreement would be entered into - the final form of which has been agreed with the signatory pages being held in escrow by a trustee who would be required to release them upon being served with a notice of exercise of the option. The Buyer only has the right to terminate the agreement in the event of a material adverse change in the trading of NGSoft. The Group's option is exercisable up to and including 1 March 2021, which, in accordance with the terms of the Option Agreement, can be extended by the Group to 17 May 2021 under certain predefined circumstances. If the Group does not exercise its option, it will be required to pay the Buyer a consideration of up to NIS 7.9m in cash. The Group will update the market in due course. Enquiries:
ADVFN Advertorial
Your Recent History
LSE
BVC
Batm Advan..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210519 00:26:24